,
January 2026: Amgen completed Phase 3 enrollment for MariTide (AMG 133) in the MARITIME-Obesity trial, with interim efficacy data expected in Q3 2026 that will position the monthly injection GLP-1/GIP antagonist as a once-monthly obesity treatment alternative
Type 2 diabetes, in particular, has seen a continuous increase in prevalence, driven by lifestyle shifts and population aging, especially in Westernized societies, where these factors contribute to rising obesity rates
Kit came quickly and it is easy to use
For more information, including how to opt out, see our Cookies and Pixels Policy and Privacy Policy .
The second explanation, supported by morphological and behavioral evidence, is that the venom functions primarily as a deterrent against predators, not a predatory tool